Kingfisher International Inc.
  • Home
  • About KFI
    • Approvals
    • Careers
  • Services
    • Safety + Efficacy Studies
    • Bioequivalence and Pharmacokinetic Studies
    • Quality Assurance
    • Clinical Pathology Laboratory
    • Statistics
  • News/Events
  • Contact Uscontact us button
Select Page

KFI is excited to announce the acquisition of an additional 5,000 sq feet of space as of September 1, 2020.

Construction on new state-of-the art canine and feline housing, enrichment, and procedure space will begin this fall. “Our focus remains to deliver high quality and compassionate science to help change and improve the lives of companion animals” said Dr. Niemuller....

KFI carries out the bioequivalence work for FDA approved Enrofloxacin Flavored Tablets for dogs and cats.

FDA’s Center for Veterinary Medicine approved Felix Pharmaceuticals Pvt. Ltd.’s ANADA for Enrofloxacin Flavored Tablets on May 21, 2020. The flavored tablets provide veterinarians with a new treatment option for disease associated with bacteria susceptible to...
Next Entries »

Recent Posts

  • KFI Conducted Feline TASS for Solensia® now Approved by FDA
  • KFI is Excited to Announce the Conditional Approval of Panoquell-CA1 by CVM
  • Coming in January of 2023 – Canine Dental Studies at KFI
  • KFI Conducted Feline TASS for Solensia® now Approved by FDA
  • KFI is delighted to announce the approval of Carprofen and Deracoxib Chewable tablets by the FDA’s Center for Veterinary Medicine for Felix Pharmaceuticals Pvt. Ltd.

Recent Comments

    KingFisher_logo
    

    (+1) 905.642.3712

    

    info@kingfisherint.com

    • Follow
    GAP_logo

    Copyright © Kingfisher International Incorporated.

    Terms of Use Policy

    Privacy Policy

    Designed by Allegra – Marketing – Print – Design